TB-1301 is a transgenic T cell targeting the NY – ESO – 1 antigen. Takara Bio has submitted a request for a clinical trial. After acceptance of the clinical trial and review by the clinical review committee of the implementation facility, Takara plans to begin registration and administration of subjects as early as April 2017.

Takara Bio news release, January 24, 2017